Dermatology

The US Food and Drug Administration has approved minocycline topical foam, 4% for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgarism in adults and pediatrics patients 9 years of age or older.

The FDA set a 2020 PDUFA action date for FMX103, a topical foam to treat papulopustular rosacea.

New findings from the 12-week pivotal JADE MONO-1 trial show the JAK1 inhibitor's benefit in skin clearance and itch relief.

The data presented at the EADV Congress in Madrid builds on the findings reported at 52 and 64 weeks in the phase 3 reSURFACE 1 and 2 trials.

New 12-week findings from a head-to-head phase 4 trial showed the Eli Lilly product's benefit for plaque psoriasis clearance.

A new phase 2b trial shows the investigative therapy significantly improves the rate of patients with hives control over 12 weeks versus its competitor.

How drug classes such as biologics have given dermatologists confidence in clearing patients' skin.

How has testing and diagnosis changed?

AKLIEF Cream, a topical cream to treat acne on the face and trunk, is expected to be available in the US in November.

New phase 2b data shows the JAK1 inhibitor is beneficial for moderate to severe adult atopic dermatitis.

How new agents, improved study outcomes, and priority on diagnosis has bettered the state of dermatologic care.

From immunotherapy to biologics, the field of allergy pharmacotherapy is looking promising.

A post hoc analysis of the OPAL Beyond and OPAL Broaden studies found tofacitinib improved skin-related symptoms and health-related quality of life in psoriatic arthritis patients with an inadequate response to csDMARDs or TNFi treatment.

How can physicians and specialists navigate testing options and potential risk factors to ensure patients are diagnosed and treated expediently and accurately?

There has been significant changes in understanding surrounding food allergy testing. What do parents need to know?

Biologics that target the immune system give doctors an opportunity to treat diseases like psoriasis and atopic dermatitis.

The human monoclonal antibody was previously approved for the treatment of adults with plaque psoriasis in July 2017.

The Allergenic Products Advisory Committee voted in favor Friday to support the BLA data for what could become the first drug indicated for food allergy desensitization.

The approval for interstitial lung disease associated with systemic sclerosis or scleroderma makes nintedanib the first therapy for the rare condition.

The new approval represents the third time the FDA approved the injection treatments for adults.

The JAK inhibitor previously approved for rheumatoid arthritis has reported early primary endpoint outcomes in its ongoing phase 3 trial.

The epicutaneous immunotherapy patch BLA was previously submitted to the FDA last year, but withdrawn due to concerns over manufacturing procedure and quality control.